Statistics from Altmetric.com
Commentary on: OpenUrl
Despite the increasing number of effective disease modifying therapies for multiple sclerosis (MS), there are no effective therapies for the progressive, neurodegenerative phase of the disease. There is now abundant experimental evidence that cannabinoids and the endocannabinoid system are protective factors in animal models of MS and also other neurodegenerative conditions. This randomised controlled trial (RCT) aimed to investigate the potential neuroprotective properties of the prototypical cannabinoid Δ 9-tetrahydrocannabinol (THC) as measured by the slowing of the progressive phase …
Competing interests None declared.
Provenance and peer review Commissioned; internally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.